PROMETHEUS® Celiac PLUS provides more comprehensive, accurate answers
- Only Prometheus genetic testing quantifies the relative risk of disease for every patient
- Clear risk stratification may enable you to prevent disease onset
- A negative predictive value (NPV) of 95% to 100% allows you to rule out celiac disease for life2
Now you can assess your patients' risk |
Category Number |
DQ Genotype Category |
Increased Risk Over
General Population3,4 |
Relative Risk |
8 |
DQ2 homozygous |
31x |
Extremely high |
7 |
DQ2/other high-risk gene |
16x |
Very high |
6 |
DQ2/DQ8 |
10x |
Very high |
5 |
DQ8 homozygous |
10x |
High |
4 |
DQ2 heterozygous |
10x |
High |
3 |
DQ8 heterozygous |
2x |
Moderate |
2 |
DQ2/other low-risk gene |
< 1x |
Low |
1 |
DQ2-, DQ8- |
< 0.1x |
Extremely low |
Most celiac patients carry either the DQ2 haplotype (about 95% of celiacs) or the DQ8 haplotype (about 5% of celiacs). There are two DQ2 haplotypes, but only one DQ8 haplotype—specific combinations may confer different risks for the development of celiac disease, as shown above.
References:
2. Kaukinen K, Partanen J, Mäki M, Collin P. HLA-DQ typing in the diagnosis of celiac disease. Am J Gastroenterol. 2002;97(3):695-699.
3. Pietzak M, Schofield T. HLA-DQ2 homozygotes are associated with a 31-fold increased risk of EMA positivety in a large sample of sera (n = 4152) from patients at risk for celiac disease [DDW abstract]. Gastroenterology. 2007;132(7):2585.
4. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter
study. Arch Intern Med. 2003;163(3):286-292.
 |
